Clinical Trial Detail

NCT ID NCT04200443
Title Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Northwestern University
Indications

uterus leiomyosarcoma

sarcoma

leiomyosarcoma

Therapies

Cabozantinib + Temozolomide

Age Groups: adult senior

No variant requirements are available.